November 15, 2026 · JAMA · DOI: 10.1001/jama.2026.24796

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.

Listen to this summary

This phase 3, double-blind, placebo-controlled trial asked whether once-weekly subcutaneous ribupatide, a dual GIP/GLP-1 receptor agonist, produces meaningful weight loss in adults with overweight or obesity (without diabetes) in China. Over 48 weeks, participants receiving 2, 4, or 6 mg ribupatide lost 10.7%, 16.4%, and 17.7% of their body weight, respectively, versus 1.4% with placebo, and 69–88% of treated participants achieved at least 5% weight loss compared with 16% on placebo. Gastrointestinal adverse events were the most common side effects (47–63% vs 23% with placebo), but few participants discontinued treatment because of them.

Lin Zhao, Ying Chen, Zhifeng Cheng, Dan Zhu, Qifu Li, Hanqing Cai, Yuan Hui, Qi Wang, Junfeng Han, Zongyou Cheng, Guiping Li, Shumei Zhong, Jinyang Wang, Lianwei Wang, Chao Meng, Shu Li, Hongye Su, Yi Xu, Meifang Zeng, Yue Zuo, Lei Zhang, Wenhua Wei, Lihao Wang, Yike Wang, Minzhi Lv, Hong Chen, Xiaoying Li

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play